Dr Ruggiero Pinto de Sa Gaspar, Director of Regulation and Pre-Rehabilitation, was answering a press question about the links between the vaccine and cerebral venous sinus thrombosis, a rare blood clotting syndrome.
The European Medicines Agency (EMA) on Tuesday denied it had proven any link, after reports that one of its experts stated there was a link.
Expert meetings are ongoing
Meanwhile, the EMA committee that monitors drug safety is meeting to evaluate the data, which is also being reviewed by a UK regulatory body. Who is the It continues both actions.
Dr. Pinto de Sa Gaspar said: “What we can say is that the assessment that we have at the moment, and this is under consideration by experts, is that the risk-benefit assessment of the vaccine is still largely positive.”
He stated that “coagulation events” are rare, and are now classified in terms of their distribution in the population.
He added: “At the present time, there is no evidence that the benefit-risk assessment of the vaccine needs to be changed.” “And we know from data from countries like the UK and others, that the benefits are really important in terms of reducing deaths in the population being vaccinated.”
The WHO’s Global Vaccine Safety Advisory Committee is due to meet on Wednesday, which will also look at the data, with an expected result later in the week.
Stigma and virus variants
Many people, including health experts, have been referring to the variants by countries in which they were first discovered, which is something the UN agency wants to change.
“We need to ensure that none of the names used lead to unintentionally stigmatizing a person, surname or location,” said Dr Maria Van Kerhove, WHO Technical Leader on COVID-19. Question from a South African journalist.
“There should be no stigma attached to discovering these viruses, and unfortunately we still see that happen.”
Currently there are three variants: B117, first identified in the UK; B 1.351, which was first identified in South Africa, and P1, a variant that was first detected in Japan but is spreading in Brazil.
More to track …
Bulletin Observer Health
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?